PatientsVille.com LogoPatientsVille.com

Hyperkalemia | Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

Hyperkalemia research study

What is the primary objective of this study?

To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.

Who is eligible to participate?

Inclusion criteria: - in-patients treated with concurrent potassium-increasing drugs Exclusion criteria: - outpatients; in-patients on wards without computerized physician order entry (i.e. patients treated in the ICU)

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Hyperkalemia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Behavioral:decision support in potassium-inc. drug-drug-interactionsdisplay of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

computer-based reminders and alertsBehavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)

no computer-based reminders or alertsBehavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

Study Status

Completed

Start Date: January 2014

Completed Date: January 2015

Phase: N/A

Type: Interventional

Design:

Primary Outcome: Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions

Secondary Outcome: Frequency of hyperkalemia during potassium-increasing drug-drug-interactions

Study sponsors, principal investigator, and references

Principal Investigator: Juerg Blaser, PhD, Prof

Lead Sponsor: University of Zurich

Collaborator:

More information:https://clinicaltrials.gov/show/NCT02020317

Eschmann E, Beeler PE, Kaplan V, Schneemann M, Z√ľnd G, Blaser J. Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug-drug interactions. Eur J Clin Pharmacol. 2014 Feb;70(2):215-23. doi: 10.1007/s00228-013-1597-2. Epub 2013 Oct 23.

Discuss Potassium